Economic burden of toxicities associated with metastatic colorectal cancer treatment regimens containing monoclonal antibodies.


OBJECTIVES Little is known about toxicity-related costs of monoclonal antibody treatments in metastatic colorectal cancer. This study aimed to identify toxicities associated with bevacizumab, cetuximab, and panitumumab and estimate the direct costs of these toxicities. METHODS Grade 3 and 4 toxicities were identified by a comprehensive literature search… (More)
DOI: 10.3111/13696998.2011.650774


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.